Cardiopulmonary function in breast cancer patients versus healthy control women

DOI: https://doi.org/10.5114/pq.2020.89810

Tetiana Odynets¹, Yuriy Briskin², Oksana Ikkert³, Valentina Todorova⁴, Anzhelika Yefremova⁵

¹ Department of Physical Rehabilitation, Khortytsya National Academy, Zaporizhzhya, Ukraine
² Department of Theory of Sport and Physical Culture, Lviv State University of Physical Culture, Lviv, Ukraine
³ Department of Human and Animals Physiology, Ivan Franko National University of Lviv, Lviv, Ukraine
⁴ Department of Gymnastics and Martial Arts, South Ukrainian National Pedagogical University named after K.D. Ushynsky, Odessa, Ukraine
⁵ Department of Physical Education and Sport, Ukrainian State University of Railway Transport, Kharkiv, Ukraine

Abstract

Introduction. The study investigated cardiopulmonary function in breast cancer patients versus healthy control women.

Methods. Overall, 115 women after breast cancer surgery and 50 healthy controls were included. The outcome measures were spirometric and hemodynamic parameters.

Results. Most of the investigated parameters in breast cancer patients were significantly lower than in healthy women. The actual vital capacity (VC) was significantly lower by 0.34 l (p < 0.001), forced vital capacity (FVC) by 0.25 l (p < 0.001), forced expiratory volume in 1 second (FEV1) by 0.26 l (p < 0.001), peak expiratory flow (PEF) by 0.95 l/s (p < 0.001), maximum expiratory flow25 (MEF25) by 0.98 l/s (p < 0.001), maximum expiratory flow50 (MEF50) by 0.65 l/s (p < 0.001), expiratory reserve volume by 0.48 l (p < 0.001), maximal voluntary ventilation by 22.73 l/min (p < 0.001). The percentage of predicted values of VC, FVC, FEV1, PEF, MEF25, and MEF50 was lower by 9.93% (p < 0.001), 7.39% (p < 0.001), 8.87% (p < 0.001), 15.7% (p < 0.001), 18.09% (p < 0.001), and 15.96% (p < 0.001), respectively. As for the cardiovascular system, the actual stroke volume was higher in the control group compared with the main group by 12.20 ml/beat (p < 0.001), stroke index by 8.85 ml/beat/m2 (p < 0.001), cardiac output by 0.87 l/min (p < 0.001), left ventricular work by 0.96 g · m/beat (p < 0.001), LVP by 0.26 W (p < 0.001).

Conclusions. Cancer treatment negatively affected most cardiopulmonary parameters. The results support the need for physiotherapy intervention in breast cancer patients after treatment.

Key words: hemodynamics, spirometry, cardiorespiratory system, breast cancer

Introduction

There is a growing body of research that emphasizes that breast cancer is a common pathology of women throughout the world [1, 2]. Patients who underwent breast cancer surgery and adjuvant cancer therapies are associated with several physical health problems, decrease in upper limb strength, lymphedema, shoulder pain, fatigue, cardiotoxicity, and issues related to peak oxygen uptake, cardiovascular endurance, and respiratory function [3–6].

Recent studies have shown high prevalence of cardiovascular side effects being important targets for interventions in breast cancer survivors [7–11]. It has been reported that breast cancer survivors often experience activity-related dyspnoea, radiation pneumonitis, deconditioning, respiratory muscle weakness, impaired lung diffusion, and exercise intolerance [12–19]. Considering the high frequency of cardiovascular risk factors, radiation pneumonitis, and respiratory muscle weakness, it is necessary to provide management of women after breast cancer surgery for implementing rehabilitation programmes.

The hypothesis of this study is that women with breast cancer have reduced cardiopulmonary function compared with age-matched healthy controls. Consequently, the aim of the study was to investigate features of cardiopulmonary function in breast cancer patients versus healthy control women.

Subjects and methods

A total of 115 women after breast cancer surgery (main group) and 50 age-matched healthy women (control group) were involved in the study.

Inclusion criteria for breast cancer patients were: women aged 50–60 years, I–II cancer stage, radical mastectomy by Madden, presence of lymphedema, impairment of active range of motion in the shoulder joint, decrease in upper limb strength, time after surgery up to 6 months. The focus was on women aged 50–60 years because the incidence of breast cancer was the highest in this age category. All the patients underwent radiation therapy. Women were excluded if they had chronic nonspecific lung disease, metastatic disease, congestive heart failure, III–IV cancer stages, period after surgery of more than 6 months.

The following respiratory parameters were measured: vital capacity (VC, l), forced vital capacity (FVC, l), forced expiratory volume in 1 second (FEV1, l), peak expiratory flow (PEF, l/s), maximum expiratory flow25 (MEF25, l/s), maximum expiratory flow50 (MEF50, l/s), maximal voluntary ventilation (MVV, l/min), inspiratory reserve volume (IRV, l), expiratory reserve volume (ERV, l). Obstructive disorders were identified only with FEV1 < 80% predicted and FVC/ERV < 70%. Restrictive disorders were identified only with FEV1 reduced (< 80% of predicted normal), FVC reduced (< 80% of predicted normal), and FEV1/
The following hemodynamic indicators were assessed: stroke volume (SV, ml/beat) – amount of blood pumped by the left ventricle at each heartbeat, cardiac output (CO, l/min) – amount of blood pumped by the left ventricle each minute, stroke index (SI, ml/beat/m²) – stroke volume normalized for body surface area, systemic vascular resistance (SVR, dyn · s/cm⁵) – the resistance to the flow of blood in the vasculature, left ventricular work (LVW, g · m/beat) – an indicator of the amount of work the left ventricle must perform to pump blood each minute, left ventricular power (LWP, W) – left ventricle work performed per time unit [22]. Hemodynamic indicators were assessed with the KARDIOLAB electrocardiographic complex (Scientific and Technological Centre of Radio-Electronic Medical Equipment and Technologies XAI-Medica of the National Aerospace University, Kharkiv, Ukraine, registration certificate number 6037/2007, conformity certificate number UA-MI/2/2p-2765–2009).

The measurements of respiratory and hemodynamic parameters were established as absolute volumes and percentages of the predicted values. The independent researcher who assessed the spiographic and hemodynamic parameters was blinded to the group assignment of the participants.

Statistical analysis

The analysis of respiratory and hemodynamic parameters of breast cancer patients and age-matched healthy controls was performed by using the Statistica for Windows (version 8.00) software. The distribution of the data recorded was tested with the Shapiro-Wilk test. This analysis was performed as a preliminary measure before parametric calculations of the analysis of difference. Independent t-tests served to analyse the cardiopulmonary parameters between groups.

Ethical approval

The research related to human use has complied with all the relevant national regulations and institutional policies, has followed the tenets of the Declaration of Helsinki, and has been approved by the Ethics Committee of Khortytsia National Academy (number 2017/12–11).

Informed consent

Informed consent has been obtained from all individuals included in this study.

Results

Demographic and treatment-related characteristics of the studied women are given in Table 1. A comparison of respiratory function parameters between the main group and the control group is presented in Table 2. The results presented in Table 2 show that most indicators of lung function in women with breast cancer were significantly lower as compared with healthy controls.

In the breast cancer patients, the actual VC was significantly lower by 0.34 l (p < 0.001), FVC by 0.25 l (p < 0.001), FEV₁ by 0.26 l (p < 0.001), PEF by 0.95 l/s (p < 0.001), MEF₂₅ by 0.98 l/s (p < 0.001), MEF₅₀ by 0.65 l/s (p < 0.001), ERV by 0.48 l (p < 0.001), MVV by 22.73 l/min (p < 0.001). The percentage of predicted values of VC, FVC, FEV₁, PEF, MEF₂₅, and MEF₅₀ was lower by 9.93% (p < 0.001), 7.39% (p < 0.001), 8.87% (p < 0.001), 15.7% (p < 0.001), 18.09% (p < 0.001), and 15.96% (p < 0.001), respectively.

The comparison of IRV did not show a statistically significant difference between women with breast cancer and

| Table 1. Demographic and treatment-related characteristics of the participants |
|--------------------------|--------------------------|--------------------------|
| Characteristics         | Main group (n = 115)     | Control group (n = 50)   | p   |
| Age (M ± m)              | 57.44 ± 2.16             | 57.69 ± 2.34             | > 0.05 |
| Race                     |                          |                          |      |
| White, n (%)             | 113 (98%)                | 49 (98%)                 | > 0.05 |
| Black, n (%)             | 2 (2%)                   | 1 (2%)                   | > 0.05 |
| Married/committed relation, n (%) | 88 (77%)                | 37 (74%)                 | > 0.05 |
| High school graduate, n (%) | 73 (64%)                | 31 (62%)                 | > 0.05 |
| College graduate, n (%)  | 29 (25%)                 | 14 (28%)                 | > 0.05 |
| Post-graduate, n (%)     | 13 (11%)                 | 5 (10%)                  | > 0.05 |
| Body mass index, kg/m² (M ± m) | 25.92 ± 0.42           | 26.01 ± 0.81             | > 0.05 |
| Treatment                |                          |                          |      |
| Radiotherapy, n (%)      | 98 (85%)                 | –                        | –     |
| Chemotherapy, n (%)      | 17 (15%)                 | –                        | –     |
| Surgery type (Madden mastectomy), n (%) | 115 (100%)            | –                        | –     |
| Time after surgery (months) | 5.23 ± 0.32            | –                        | –     |
| Cancer stage             |                          |                          |      |
| Stage 1, n (%)           | 33 (29%)                 | –                        | –     |
| Stage 2, n (%)           | 82 (71%)                 | –                        | –     |

M – mean, m – error of mean
age-matched healthy controls. A detailed analysis of VC revealed normal values only in 20% of breast cancer patients. FVC was normal in 28%, PEF in 9%, MEF25 in 30%, and MEF50 in 35%.

A comparison of hemodynamic parameters between the main group and the control group is presented in Table 3. It was found that the actual value of SV was higher in women of the control group compared with the main group by 12.20 ml/beat ($p < 0.001$), Si by 8.85 ml/beat/m² ($p < 0.001$), Co by 0.87 l/min ($p < 0.001$), LVW by 0.96 g · m/beat ($p < 0.001$), and LVP by 0.26 W ($p < 0.01$). The percentage of predicted values of SV, LVW, and LVP was lower by 22.11% ($p < 0.001$), 21.89% ($p < 0.001$), and 13.77% ($p < 0.001$), respectively. Women with breast cancer had higher results for SVR by 424.29 dyn · s/cm⁵ and its percentage of predicted value by 30.47% ($p < 0.001$) compared with the controls. It was an unfavourable prognostic factor for raising blood pressure in breast cancer patients.

With the consideration of the baseline values of cardiac index and SVR, the following types of blood flow regulation were identified among the breast cancer women: hypokinetic in 80% of the patients, normokinetic in 16%, and eukinetic only in 4%. At the same time, the hypokinetic type of regulation was observed only in 22% of the age-matched healthy control women, normokinetic in 72%, and hyperkinetic in 6%.

| Indicator                                      | Groups                          | $P$   |
|-----------------------------------------------|---------------------------------|-------|
| **Table 2. Comparison of spirometry parameters ($M \pm m$) between the groups** |                                 |       |
| Indicator                                      | Main group ($n = 115$) | Control group ($n = 50$) |       |
| **Vital capacity (l)**                        | Actual $2.45 \pm 0.02$ | $2.79 \pm 0.07$< 0.001 |       |
|                                               | % of predicted $78.33 \pm 0.94$ | $88.26 \pm 2.30$ < 0.001 |       |
| **Forced vital capacity (l)**                  | Actual $2.36 \pm 0.02$ | $2.61 \pm 0.05$ < 0.001 |       |
|                                               | % of predicted $79.97 \pm 0.88$ | $87.36 \pm 1.69$ < 0.001 |       |
| **Forced expiratory volume in 1 second (l)**   | Actual $2.03 \pm 0.02$ | $2.29 \pm 0.06$ < 0.001 |       |
|                                               | % of predicted $83.35 \pm 1.29$ | $92.22 \pm 2.64$ < 0.001 |       |
| **Peak expiratory flow (l/s)**                 | Actual $3.23 \pm 0.09$ | $4.18 \pm 0.19$ < 0.001 |       |
|                                               | % of predicted $55.66 \pm 1.61$ | $71.36 \pm 3.28$ < 0.001 |       |
| **Maximum expiratory flow25 (l/s)**            | Actual $2.88 \pm 0.08$ | $3.86 \pm 0.17$ < 0.001 |       |
|                                               | % of predicted $56.17 \pm 1.58$ | $74.26 \pm 3.43$ < 0.001 |       |
| **Maximum expiratory flow50 (l/s)**            | Actual $2.82 \pm 0.07$ | $3.47 \pm 0.16$ < 0.001 |       |
|                                               | % of predicted $79.00 \pm 2.25$ | $94.96 \pm 4.33$ < 0.001 |       |
| **Inspiratory reserve volume (l)**             | $1.11 \pm 0.03$ | $1.24 \pm 0.07$ > 0.05 |       |
| **Expiratory reserve volume (l)**              | $0.70 \pm 0.03$ | $1.18 \pm 0.09$ < 0.001 |       |
| **Maximal voluntary ventilation (l/min)**      | $58.86 \pm 1.52$ | $81.59 \pm 3.94$ < 0.001 |       |

$M$ – mean, $m$ – error of mean

| Indicator                                      | Groups                          | $P$   |
|-----------------------------------------------|---------------------------------|-------|
| **Table 3. Comparison of hemodynamic parameters ($M \pm m$) between the groups** |                                 |       |
| Indicator                                      | Main group ($n = 115$) | Control group ($n = 50$) |       |
| **Stroke volume (ml/beat)**                   | Actual $46.25 \pm 0.87$ | $58.45 \pm 2.05$ < 0.001 |       |
|                                               | % of predicted $72.87 \pm 1.22$ | $94.98 \pm 3.27$ < 0.001 |       |
| **Stroke index (ml/beat/m²)**                  | Actual $26.05 \pm 0.48$ | $34.90 \pm 1.29$ < 0.001 |       |
| **Cardiac output (l/min)**                     | $3.39 \pm 0.05$ | $4.26 \pm 0.13$ < 0.001 |       |
| **Systemic vascular resistance (dyn · s/cm³)**  | Actual $2116.43 \pm 34.93$ | $1692.140 \pm 55.94$ < 0.001 |       |
|                                               | % of predicted $133.63 \pm 2.19$ | $103.16 \pm 3.32$ < 0.001 |       |
| **Left ventricular work (g · m/beat)**        | Actual $4.14 \pm 0.07$ | $5.10 \pm 0.15$ < 0.001 |       |
|                                               | % of predicted $75.31 \pm 1.20$ | $97.20 \pm 3.17$ < 0.001 |       |
| **Left ventricular power (W)**                 | Actual $2.11 \pm 0.04$ | $2.37 \pm 0.08$ < 0.01 |       |
|                                               | % of predicted $78.65 \pm 1.55$ | $92.42 \pm 3.30$ < 0.001 |       |

$M$ – mean, $m$ – error of mean
Discussion

It was identified that women after breast cancer surgery and adjuvant therapy had impaired cardiopulmonary function compared with controls. A great deal of research [2–4, 23, 24] indicates that women who underwent breast surgery and adjuvant therapy are more likely to present a higher risk of cardiotoxicity, reduced peak oxygen consumption, and impaired cardiopulmonary parameters. The importance of the problem is underlined by the presence of numerous physical exercise interventions [8–11, 25–28] for improving life quality and functional state of the cardiovascular system in breast cancer survivors.

On the basis of the analysis of the cardiovascular system functional state carried out by rheography, it was found that most indicators of central hemodynamics were reduced with the exception of SVR, which was significantly higher than the normal values. Most breast cancer patients (80%) had the hypokinetic type of blood flow regulation, while the healthy controls (72%) were normokinetic.

All of the obtained respiratory parameters turned out to be decreased in breast cancer patients. Restrictive and obstructive types of respiratory dysfunction were revealed. These findings are supported by studies that confirm that mastectomy leads to a decrease in PEF and forced expiratory flow.

Our observations complement the research [4, 11, 24] on pulmonary function, which was characterized by a decrease in the relative values of VC, FEV1, MEF25, MEF50, MVV, and ERV, indicating the presence of obstructive disorders of the respiratory system and its reduced functionality in breast cancer patients.

Limitations

This study has important limitations. Our findings are based on a small sample and the obtained results may not be generalizable to all women population suffering from breast cancer.

Conclusions

In conclusion, we confirm that the performed breast cancer treatment negatively affects most parameters of the cardiorespiratory system in women. The results of the present study support the continued need and feasibility of physiotherapy intervention in breast cancer patients after completion of treatment.

Prospects for further study will be directed at determining the effectiveness of individualized physical interventions in breast cancer patients with cardiopulmonary function disorders.

Disclosure statement

No author has any financial interest or received any financial benefit from this research.

Conflict of interest

The authors state no conflict of interest.

References

1. DeSantis C, Ma J, Bryan L, Jemal A. Breast cancer statistics, 2013. CA Cancer J Clin. 2014;64(1):52–62; doi: 10.3322/caac.21203.

2. VerbeLEN H, Gebrueurs N, Tjalma W. Late effects of cancer treatment in breast cancer survivors. South Asian J Cancer. 2015;4(4):182; doi: 10.4103/2278-330X.175956.

3. Jones LW, Courneya KS, Mackey JR, Muss HB, Pituskin EN, Scott JM, et al. Cardiopulmonary function and age-related decline across the breast cancer survivorship continuum. J Clin Oncol. 2012;30(20):2530–2537; doi: 10.1200/JCO.2011.39.0014.

4. Suesada MM, Carvalho HA, Albuquerque ALP, Salge JM, Stuart SR, Takagaki TY. Impact of thoracic radiotherapy on respiratory function and exercise capacity in patients with breast cancer. J Bras Pneumol. 2018;44(6):469–476; doi: 10.1590/S1806-3756201700000120.

5. Howden EJ, Bigaran A, Beaudry R, Fraser S, Selig S, Foulkes S, et al. Exercise as a diagnostic and therapeutic tool for the prevention of cardiovascular dysfunction in breast cancer patients. Eur J Prev Cardiol. 2019;26(3):305–315; doi: 10.1177/2047487318811181.

6. Zagar TM, Cardinale DM, Marks LB. Breast cancer therapy-associated cardiovascualr disease. Nat Rev Clin Oncol. 2016;13(3):172–184; doi: 10.1038/nrclinonc.2015.171.

7. Odynets T, Briskin Y. Effect of individualised physical rehabilitation programmes on the functional state of the cardiorespiratory system in women with post-mastectomy syndrome. Int J Ther Rehabil. 2019;26(2):1–10; doi: 10.12968.ijtr.2018.0003.

8. Odynets T, Briskin Y, Zakharin A, Yefremova A. Influence of a water physical rehabilitation program on the hemodynamic parameters in breast cancer survivors. Physiother Quart. 2019;27(2):6–10; doi: 10.5114/pq.2019.84267.

9. Odynets T, Briskin Y, Pityn M. Effect of individualized physical rehabilitation programs on respiratory function in women with post-mastectomy syndrome. Physiother Theory Pract. 2019;35(5):419–426; doi: 10.1080/09593985.2018.1444117.

10. Bonsignore A, Marzolini S, Oh P. Cardiac rehabilitation for women with breast cancer and treatment-related heart failure compared with coronary artery disease: a retrospective study. J Rehabil Med. 2017;49(3):277–281; doi: 10.2340/16501977-2203.

11. Kulik-Parobczy I. Evaluation of the effectiveness of physiotherapy in patients after oncological breast cancer treatment based on spirometric indicators. Contemp Oncol. 2019;23(1):47–51; doi: 10.5114/wo.2019.82929.

12. Foulkes SJ, Howden EJ, Bigaran A, Janssens K, Antill Y, Loi S, et al. Persistent impairment in cardiopulmonary fitness after breast cancer chemotherapy. Med Sci Sports Exerc. 2019;51(8):1573–1581; doi: 10.1249/MSS.00000000000001970.

13. Yu AF, Jones LW. Breast cancer treatment-associated cardiovascular toxicity and effects of exercise countermeasures. Cardiooncology. 2016;2(2):1; doi: 10.1186/s40959-016-0011-5.

14. Fabian C. Prevention and treatment of cardiac dysfunction in breast cancer survivors. Adv Exp Med Biol. 2015;862:213–230; doi: 10.1007/978-3-319-16366-6_14.

15. Hooning MJ, Botma A, Aleman BM, Baaijens MH, Bartelink H, Klijn JG, et al. Long-term risk of cardiovascular disease in 10-year survivors of breast cancer. J Natl Cancer Inst. 2007;99(5):365–375; doi: 10.1093/jnci/djk064.

16. Martel S, Maurer C, Lambertini M, Pondé N, De Azambuja E. Breast cancer treatment-induced cardiotoxicity. Expert Opin Drug Saf. 2017;16(9):1021–1038; doi: 10.1080/14740338.2017.1351541.

17. Rygiel K. Cardiotoxic effects of radiotherapy and strategies to reduce them in patients with breast cancer: an overview. J Cancer Res Ther. 2017;13(2):186–192; doi: 10.4103/0973-1482.187303.

18. Peel AB, Thomas SM, Dittus K, Jones LW, Lakoski SG. Cardiorespiratory fitness in breast cancer patients: a call
for normative values. J Am Heart Assoc. 2014;3(1):e000432; doi: 10.1161/JAHA.113.000432.

19. Cueva JF, Antolin S, Calvo L, Fernández I, Ramos M, de Paz L, et al. Galician consensus on management of cardiotoxicity in breast cancer: risk factors, prevention, and early intervention. Clin Transl Oncol. 2017;19(9):1067–1078; doi: 10.1007/s12094-017-1648-8.

20. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, et al. Standardisation of spirometry. Eur Respir J. 2005;26(2):319–338; doi: 10.1183/09031936.05.00034805.

21. American Thoracic Society/European Respiratory Society. ATS/ERS statement on respiratory muscle testing. Am J Respir Crit Care Med. 2002;166(4):518–624; doi: 10.1164/rccm.166.4.518.

22. Cybulski G. Ambulatory impedance cardiography: the systems and their applications. Heidelberg: Springer; 2011.

23. Patnaik JL, Byers T, DiGuiseppi C, dabelea d , denberg Td. Cardiovascular disease competes with breast cancer as the leading cause of death for older females diagnosed with breast cancer: a retrospective cohort study. Breast Cancer Res. 2011;13(3):R64; doi: 10.1186/bcr2901.

24. Spyropoulou D, Leotsinidis M, Tsiamita M, Spiropoulos K, Kardamakis D. Pulmonary function testing in women breast cancer treated with radiotherapy and chemotherapy. In Vivo. 2009;23(5):867–871.

25. Sowa M, Głowacka-Mrotek I, Monastyrska E, Nowikiewicz T, Mackiewicz-Milewska M, Hagner W, et al. Assessment of quality of life in women five years after breast cancer surgery, members of breast cancer self-help groups – non-randomized, cross-sectional study. Contemp Oncol. 2018;22(1):20–26; doi: 10.5114/wo.2018.74389.

26. Wtoch A, Bocian A, Biskup M, Krupnik S, Opuchlik A, Ridan T, et al. Effectiveness of specific types of structured physical activities in the rehabilitation of post-mastectomy women: a systematic review. Med Stud. 2018;34(1):86–92; doi: 10.5114/ms.2018.74826.

27. Odynets T, Briskin Y, Sydorko O, Tyschenko V, Putrov S. Effectiveness of individualized physical rehabilitation programs on post-mastectomy pain in breast cancer survivors. Physiother Quart. 2018;26(3):1–5; doi: 10.5114/pq.2018.78377.

28. Odynets T, Briskin Y, Perederiy A, Pityn M, Svistelnyk I. Effect of water physical therapy on quality of life in breast cancer survivors. Physiother Quart. 2018;26(4):11–16; doi: 10.5114/pq.2018.79741.